15 news items
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
as this study is an ongoing example of our steadfast commitment to working with leading data science companies to drive innovation and assist patients
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK
31 May 24
-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
d5wwh xizthvenmoskdj9fi
TAK
16 May 24
in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our
95no6gaogijkgx57sbb7pbt5wpr726p37mjmjrhnl1he917m2c4
ACIU
TAK
13 May 24
as well as worldwide commercialization.
"At Takeda, we are committed to tackling some of society's most
bixa8z4f5v9v13i
ACIU
TAK
13 May 24
development and be responsible for all global regulatory activities as well as worldwide commercialization. "At Takeda, we are committed
sy76y8p4ds4vhcm315plse2zncvdewwx3d2btij1szurb
TAK
9 May 24
Committed to 100-250 Basis Points Core Operating
vn9eljggxbtldpugrw 16l2a
TAK
26 Apr 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
vwd7570e3zz5et1gebd8pk8kpka12tamxshsd0zm1scqjuagy8ufugyl1c
TAK
22 Apr 24
biopharmaceutical company headquartered in Japan, we are guided by our commitment
s8ud8ad92y9fcjcfdhtcwe1ghu40g2v8g9q4tx4z9llmbcdeqzry3b
TAK
18 Apr 24
Business Unit, Takeda. "Our development of a subcutaneous option demonstrates Takeda's commitment to meeting the very real needs of those living
y4j9pv2gcw7
TAK
27 Mar 24
lives and work. As medical teams and individuals in this community, we are committed to promoting the spirit of unlimited support with the goal
1b28zn
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
nxp28i3p48enl0ck njllii7q
TAK
26 Mar 24
with new possibilities and continue our 70-plus year commitment to the rare disease community."The approval is supported by the totality
- Prev
- 1
- Next